Medibank Private Limited (ASX:MPL): Health Insurance Results and Care Services Expansion

Aditi Sarkar

20 October 2026 09:42 PM AEDT

Medibank Private Limited (ASX:MPL): Health Insurance Results and Care Services Expansion

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Medibank Private Limited (ASX:MPL) reported FY26 developments across insurance and care services.
The group said FY26 claims paid totalled AUD 6.9 billion and customer value measures approached AUD 300 million.
Amplar Health supported more than four million GP consultations across 169 clinics during FY26.
Medibank shares closed at AUD 4.78 on 20 October 2026, up 0.63% for the session.

Medibank Private Limited provides Australian private health insurance through the Medibank and ahm brands and delivers healthcare services through Amplar Health. The company has reported its FY26 annual results and described further activity in primary care, prevention and virtual health. On 20 October 2026, Medibank Private Limited (ASX:MPL) closed at AUD 4.78, gaining 0.63% over the trading day. Its insurance operations, health services expansion and healthcare cost pressures provide the current operational context.

Company Business

Medibank's Australian operations span resident and non-resident private health cover as well as healthcare delivery. Insurance products include hospital and extras cover, while the ahm brand provides another customer-facing insurance offering. Amplar Health operates across primary care, community care and other health services, including clinician-supported programs and digital care access. The businesses serve individual customers, patients and partners within the Australian health system.

Medibank Private Limited (ASX:MPL) also operates health engagement and prevention programs alongside its insurance products. Its Live Better rewards program passed one million members during FY26, according to the company.

Recent Development

In August 2026, Medibank released its full-year results for the year ended 30 June. The company reported approximately six million people supported across its insurance and healthcare activities, with its annual reporting describing further expansion of the Amplar Health service network. It also reported 334,000 enrolments in everyday prevention programs and delivery of 36,000 clinician-guided prevention services during FY26.

The company stated that 57% of Medibank policyholders engaged with its health and wellbeing offerings during the year. Amplar Health supported more than four million general-practitioner consultations through 169 GP and medical clinics.

Its shareholder calendar confirms a final dividend payment date of 8 October 2026 and schedules the 2026 annual general meeting for 18 November.

Financial Performance and Sector Context

Medibank said total health insurance claims paid reached AUD 6.9 billion in FY26, alongside almost AUD 300 million of additional value delivered to customers. The company also stated that Medibank Health accounted for around 12% of group operating profit in FY26, reflecting the role of non-insurance services within the business mix.

For the six months ended 31 December 2025, the company's HY26 report recorded group revenue from external customers of AUD 4,503.5 million, up 5.5% from the corresponding period. Group operating profit increased 6.0% to AUD 381.7 million. Meanwhile, net profit after tax attributable to shareholders fell 11.0% to AUD 302.9 million, and underlying net profit declined 0.3% to AUD 297.8 million.

Private health insurance faces a continuing interaction between premiums, healthcare utilisation, treatment costs and affordability. Medibank announced a 5.10% average premium increase effective 1 April 2026 for Medibank and ahm policies, following federal approval. Medibank Private Limited (ASX:MPL) is also exposed to the investment returns on assets supporting its insurance activities.

Risks to Consider

Claims inflation and shifts in hospital utilisation remain important insurance risks. Affordability pressures may influence customer decisions about products and cover levels. Health services growth introduces execution requirements involving clinicians, clinical quality, technology, operating costs and integration of care networks. Regulatory settings for private health insurance and data protection obligations also shape expenditure and business practices.

For Medibank Private Limited (ASX:MPL), investment income may fluctuate independently of underlying insurance activity. The HY26 disclosure recorded AUD 15.0 million of non-recurring cybercrime-related costs, including security and legal expenditures.

What to Watch Next

The 18 November 2026 annual general meeting is a defined upcoming event. Subsequent disclosures can be assessed for resident and non-resident policy movements, premium and claims trends, management expense control and the contribution of Amplar Health. Further detail on clinic activity and uptake of prevention programs will also help clarify the progress of service delivery initiatives.

Reporting from Medibank Private Limited (ASX:MPL) may also show how changes in healthcare costs affect insurance margins, and whether growth in health services translates into operating earnings.

Key Insights

Medibank's FY26 disclosures show a business combining private health insurance with expanding healthcare services. Reported claims payments, prevention-program participation and clinic consultations demonstrate activity across both areas, while HY26 figures show how operating profit and attributable earnings can follow different paths. The principal items to monitor are claims costs, policyholder trends, returns from healthcare service delivery and future official financial reporting.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.